BridgeBio Pharma Inc
2CL
Company Profile
Business description
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
Contact
3160 Porter Drive
Suite 250
Palo AltoCA94304
USAT: +1 650 391-9740
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
839
Stocks News & Analysis
stocks
5 star fully franked ASX dividend payer
Investors in cheap ASX share with a narrow moat enjoys a high yield, but there are risks investors should be aware of.
stocks
An undervalued stock to buy that even Warren Buffett likes
Trading at an 18% discount, this wide-moat stock is a rare find.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,886.60 | 35.90 | 0.41% |
| CAC 40 | 8,035.87 | 42.61 | -0.53% |
| DAX 40 | 25,399.21 | 24.79 | 0.10% |
| Dow JONES (US) | 51,349.92 | 131.59 | -0.26% |
| FTSE 100 | 10,636.71 | 48.17 | -0.45% |
| HKSE | 24,523.57 | 118.94 | -0.48% |
| NASDAQ | 26,797.54 | 22.84 | -0.09% |
| Nikkei 225 | 65,481.27 | 396.35 | -0.60% |
| NZX 50 Index | 13,700.41 | 16.78 | 0.12% |
| S&P 500 | 7,670.84 | 12.85 | -0.17% |
| S&P/ASX 200 | 8,709.30 | 29.60 | 0.34% |
| SSE Composite Index | 3,830.45 | 6.83 | 0.18% |